DEF 14A: Astrana Health Seeks Stockholder Approval for Amended Equity Incentive Plan and Director Elections at 2025 Annual Meeting

Astrana Health is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of Ernst & Young LLP, approve executive compensation, and approve an amended equity incentive plan.

Summary

• Astrana Health, Inc. will hold its 2025 Annual Meeting of Stockholders on June 11, 2025, in Alhambra, California.
• Stockholders will vote to elect nine directors, ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approve executive compensation on an advisory basis, and approve the Astrana Health, Inc. Amended and Restated 2024 Equity Incentive Plan.
• The board recommends voting for all director nominees, the ratification of Ernst & Young LLP, the approval of executive compensation, and the approval of the amended equity incentive plan.
• The record date for determining stockholders eligible to vote at the meeting is April 22, 2025.
• The company is asking stockholders to approve an increase of 2,000,000 shares to the equity incentive plan, bringing the total to 4,100,000 shares, and to extend the plan's term.
• As of the record date, approximately 850,000 shares remained available for issuance under the 2024 Plan.
• The company believes the increased share reserve will be sufficient for approximately three years based on historical equity grant practices.
• The board has nominated Kenneth Sim, Thomas Lam, John Chiang, Weili Dai, J. Lorraine Estradas, Mitchell Kitayama, Linda Marsh, Matthew Mazdyasni, and David Schmidt for election as directors.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook for Astrana Health, highlighting strong revenue growth and strategic initiatives. However, it also acknowledges certain risks and related party transactions, leading to a moderately positive sentiment score.

Positives

• The board is actively seeking stockholder input on executive compensation through an advisory vote.
• The company is taking steps to ensure its equity compensation plan remains competitive and effective for attracting and retaining talent.
• The company is committed to good corporate governance practices, including independent board oversight and risk management.
• The company has a compensation recovery (clawback) policy in place.
• The company has stock ownership guidelines for executives and non-employee directors.

Negatives

• The company's largest stockholder, APC, is limited to voting only 9.99% of the outstanding shares, potentially diluting their influence.
• The company has had related party transactions, including leases and service agreements with entities connected to directors and executive officers.
• There were some instances of late filings of Section 16(a) reports by executive officers.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the pending acquisition of certain businesses and assets relating to Prospect Health Systems, which may not close in a timely manner, or at all.
• The company's future results could differ materially from any future results expressed or implied by the forward-looking statements due to various risks and uncertainties.
• The company's compensation recovery policy may require the recoupment of certain incentive-based executive compensation in the event of an accounting restatement.

Future Outlook

The company agreed to acquire certain businesses and assets relating to Prospect Health System, which should significantly expand the company's provider network; the acquisition is expected to close in the middle of 2025, subject to regulatory approval and other customary closing conditions.

Industry Context

The document highlights Astrana Health's position in the value-based care market and its focus on providing high-quality, cost-effective healthcare.

Comparison to Industry Standards

• The document compares Astrana Health's stock performance to a peer group of companies in the healthcare providers and services sector as well as the health care technology industry.
• The peer group includes agilon health, inc., Alignment Healthcare, Inc., Chemed Corporation, Evolent Health, Inc., Health Catalyst, Inc., HealthEquity, Inc., NeueHealth, Inc., Premier, Inc., RadNet, Inc., Teladoc Health, Inc., and Veradigm Inc.

Related Party Transactions

• The company had leases with a real estate business managed by Dr. Lam, incurring rent expenses of approximately $4.0 million.
• The company recognized revenue of $41.3 million from AHMC and $1.6 million from Health Source MSO and incurred expenses of $34.9 million from AHMC and $0.3 million from Aurion, where Linda Marsh is an executive.
• The company had recognized risk pool revenue of $34.1 million under a risk-sharing agreement with certain AHMC hospitals.
• Arroyo Vista Family Health Center, where J. Lorraine Estradas is the CEO, provided $0.4 million in primary care services to enrollees, reimbursed by the company, and the company earned $2.2 million in management fees from Arroyo Vista Family Health Center.
• The company entered into a three-year promissory note with Sunny Village Care Center, where Kenneth Sim and Dr. Lam have ownership interests.
• The company incurred rent expenses of approximately $0.2 million from First Commonwealth Property, LLC, where Dr. Sim and Dr. Lam each had an ownership interest.
• APC paid $3.1 million in 2024 to a general surgery group solely owned by Dr. Sim for provider services.
• The company incurred approximately $3.6 million in expenses payable to Third Way Health Inc., where Brandon K. Sim is a board member.
• The company incurred approximately $0.2 million in expenses payable to The Stellar Health Group, Inc., where Dinesh Kumar is an advisory board member.
• Astrana paid approximately $0.9 million to purchase Astrana's stock from certain board members.
• Astrana paid approximately $10.6 million to purchase Astrana's stock from APC.

Stakeholder Impact

• Approval of the equity incentive plan is intended to align the interests of executives and employees with those of stockholders.
• The company is committed to supporting the professional development of its employees and providing a safe and inclusive workplace.
• The company actively engages with local communities through volunteer programs, sponsorships, and educational initiatives.
• The company is committed to protecting the privacy and security of the data of patients, employees, and others who entrust the company with their data.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will file a Current Report on Form 8-K within four business days of the 2025 Annual Meeting to publish the final voting results.
• The company intends to file a Registration Statement on Form S-8 relating to the additional shares reserved for issuance under the 2024 Plan with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended, as soon as practicable after approval of the 2024 Plan by the Company's stockholders.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, equity incentive plan, stockholders, corporate governance, related party transactions, audit committee, Ernst & Young